Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links

Merck KGaA's multiple sclerosis drug hit with partial FDA hold, adding to BTK-liver injury links

Source: 
Fierce Biotech
snippet: 

The evidence that drug-induced liver injury is a classwide problem for BTK inhibitors is mounting up. In the wake of its partial clinical holds on studies involving Biogen and Sanofi, the FDA has clamped down on trials of Merck KGaA’s contender in response to evidence of damage to the liver of two patients.